spravato fda news - Search News

FDA Approves ‘Spravato’ Nasal Spray

UPI News on MSN · 2d

FDA approves Spravato, first monotherapy nasal spray to treat depression

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,

FDA OKs Esketamine Nasal Spray Monotherapy for Resistant Depression

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not responded to at least two oral antidepressants.

Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Hosted on MSN1d

J&J’s Spravato receives FDA label expansion for depression monotherapy

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...

Johnson & Johnson's Spravato gains FDA nod to be used as a monotherapy

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

J&J's Spravato gets another lift with new FDA approval

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...

J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results